# Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

> **NCT00720135** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma
- Cutaneous B-cell Non-Hodgkin Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Intraocular Lymphoma
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Marginal Zone Lymphoma
- Small Intestine Lymphoma
- Splenic Marginal Zone Lymphoma
- Testicular Lymphoma
- Waldenstrom Macroglobulinemia

## Interventions

- **BIOLOGICAL:** DI-Leu16-IL2 immunocytokine
- **BIOLOGICAL:** rituximab
- **OTHER:** flow cytometry
- **OTHER:** immunohistochemistry staining method
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis
- **OTHER:** enzyme-linked immunosorbent assay
- **GENETIC:** reverse transcriptase-polymerase chain reaction

## Key facts

- **NCT ID:** NCT00720135
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2015-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720135, "Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00720135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*